Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

REITs pay dividends out of their funds from operations (FFO), and Vici's FFO per share is $2.61 over the last 12 months. This ...

The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.

While Humira’s 2023 loss of exclusivity hung over AbbVie’s head for years, the ascent of the Chicago drugmaker’s immunology successors Skyrizi and Rinvoq under prior CEO Richard Gonzalez has swiftl | ...

Investing some of your tax refund in stocks can help build your portfolio. The three stocks below trade at forward earnings ...

A key regulatory win could turn this under-the-radar treatment into AbbVie's next billion-dollar success story.

As STAT’s Helen Branswell writes, mRNA vaccines are the fastest to make and the easiest to mass produce.

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

ABBV’s Successful New Drugs — Skyrizi and Rinvoq AbbVie lost patent protection for Humira in the United States in January 2023 and in the EU in 2018. Humira's sales are declining due to the ...

SmithRx, a transparent, 100% pass-through modern pharmacy benefits manager (PBM), today announced a major expansion to its Connect 360 Autoimmune Prog ...